CY1122426T1 - Παραγωγα 8-υδροξυ-κινολινης - Google Patents
Παραγωγα 8-υδροξυ-κινολινηςInfo
- Publication number
- CY1122426T1 CY1122426T1 CY20191101327T CY191101327T CY1122426T1 CY 1122426 T1 CY1122426 T1 CY 1122426T1 CY 20191101327 T CY20191101327 T CY 20191101327T CY 191101327 T CY191101327 T CY 191101327T CY 1122426 T1 CY1122426 T1 CY 1122426T1
- Authority
- CY
- Cyprus
- Prior art keywords
- group
- groups
- lower alkyl
- optionally substituted
- hydrogen atom
- Prior art date
Links
- 150000004325 8-hydroxyquinolines Chemical class 0.000 title 1
- 125000000217 alkyl group Chemical group 0.000 abstract 4
- 125000003710 aryl alkyl group Chemical group 0.000 abstract 3
- 125000003118 aryl group Chemical group 0.000 abstract 3
- 125000000623 heterocyclic group Chemical group 0.000 abstract 3
- 125000004435 hydrogen atom Chemical group [H]* 0.000 abstract 3
- 150000001875 compounds Chemical class 0.000 abstract 2
- 125000005843 halogen group Chemical group 0.000 abstract 2
- 230000002378 acidificating effect Effects 0.000 abstract 1
- 125000003342 alkenyl group Chemical group 0.000 abstract 1
- 125000000753 cycloalkyl group Chemical group 0.000 abstract 1
- 201000010099 disease Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003814 drug Substances 0.000 abstract 1
- 125000000524 functional group Chemical group 0.000 abstract 1
- 230000000926 neurological effect Effects 0.000 abstract 1
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 abstract 1
- 230000036542 oxidative stress Effects 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/22—Anxiolytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/06—Free radical scavengers or antioxidants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/10—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing aromatic rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
Abstract
Η εφεύρεση αφορά σε ενώσεις του γενικού τύπου (I) και στα θεραπευτικά αποδεκτά άλατα τους (στον οποίο τύπο R1 αντιπροσωπεύει ένα άτομο υδρογόνου, κατώτερη αλκυλική ομάδα, κατώτερη αλκενυλική ομάδα, κατώτερη κυκλοαλκυλική ομάδα, αρυλική ομάδα, αραλκυλική ομάδα ή ετεροκυκλική ομάδα, όπου οι παραπάνω ομάδες είναι προαιρετικά υποκατεστημένες σε θέσεις ορθο, μετά και / ή παρά με 1, 2, 3 ή 4 ομάδες δέκτη ηλεκτρονίων ή ομάδες δότη ηλεκτρονίων, R2 αντιπροσωπεύει ένα άτομο υδρογόνου, κατώτερη αλκυλική ομάδα, αρυλική ομάδα, αραλκυλική ομάδα ή ετεροκυκλική ομάδα, όπου οι παραπάνω ομάδες είναι προαιρετικά υποκατεστημένες με ένα ή περισσότερα άτομα αλογόνου, R3 αντιπροσωπεύει μία κατώτερη αλκυλική ομάδα, αρυλική ομάδα, αραλκυλική ομάδα ή ετεροκυκλική ομάδα, όπου οι παραπάνω ομάδες είναι προαιρετικά υποκατεστημένες σε ορθο, μετά ή παρά θέση με 1, 2, 3 ή 4 ομάδες δέκτη ηλεκτρονίων που επιλέγονται από άτομα αλογόνου, τριφθορομεθύλιο ή ομάδες νίτρο ή ομάδες δότη ηλεκτρονίων ή ομάδες δότη ηλεκτρονίων, R4 αντιπροσωπεύει ένα άτομο υδρογόνου, κατώτερη αλκυλική ομάδα ή οποιαδήποτε όξινη λειτουργική ομάδα, n είναι 1 ή 2). Οι ενώσεις σύμφωνα με την εφεύρεση μπορούν να χρησιμοποιούνται στην ιατρική κυρίως για τη θεραπεία ασθενειών που σχετίζονται με νευρολογικό και/ή οξειδωτικό στρες.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| HU1000243A HUP1000243A2 (en) | 2010-05-06 | 2010-05-06 | 8-hidroxy-quinoline derivatives |
| PCT/HU2011/000043 WO2011148208A1 (en) | 2010-05-06 | 2011-05-06 | 8-hydroxy-quinoline derivatives |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CY1122426T1 true CY1122426T1 (el) | 2021-01-27 |
Family
ID=89989711
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CY20191101327T CY1122426T1 (el) | 2010-05-06 | 2019-12-17 | Παραγωγα 8-υδροξυ-κινολινης |
Country Status (20)
| Country | Link |
|---|---|
| US (1) | US8871937B2 (el) |
| EP (1) | EP2566849B1 (el) |
| JP (1) | JP5812541B2 (el) |
| KR (1) | KR101837974B1 (el) |
| CN (1) | CN102985407B (el) |
| AU (1) | AU2011256989B2 (el) |
| CA (1) | CA2798419C (el) |
| CY (1) | CY1122426T1 (el) |
| DK (1) | DK2566849T3 (el) |
| EA (1) | EA021026B1 (el) |
| ES (1) | ES2761832T3 (el) |
| HR (1) | HRP20192278T1 (el) |
| HU (2) | HUP1000243A2 (el) |
| MX (1) | MX337999B (el) |
| NZ (1) | NZ603967A (el) |
| PL (1) | PL2566849T3 (el) |
| PT (1) | PT2566849T (el) |
| RS (1) | RS59678B1 (el) |
| SI (1) | SI2566849T1 (el) |
| WO (1) | WO2011148208A1 (el) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HUP1500098A2 (hu) * | 2015-03-09 | 2016-09-28 | Avidin Kft | 8-hidroxikinolin származékok új enantiomerjei és szintézisük |
| WO2017066245A1 (en) * | 2015-10-12 | 2017-04-20 | Health Research, Inc. | Methods for inducing apoptosis in cancer cells |
| CN105367553A (zh) * | 2015-12-04 | 2016-03-02 | 广东工业大学 | 一种他克林-8-羟（胺）基喹啉衍生物及其应用 |
| HUP1600234A2 (en) | 2016-04-05 | 2017-12-28 | Mta Termeszettudomanyi Kutatokoezpont | Mdr-reversing 8-hydroxy-quinoline derivatives |
Family Cites Families (31)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6544972B1 (en) | 1997-09-25 | 2003-04-08 | Regents Of The University Of Minnesota | Methods of limiting apoptosis of cells |
| US6184210B1 (en) | 1997-10-10 | 2001-02-06 | Cytovia, Inc. | Dipeptide apoptosis inhibitors and the use thereof |
| WO1999037294A2 (en) | 1998-01-26 | 1999-07-29 | Mitokor | Mitochondria protecting agents for treating mitochondria associated diseases |
| US6737511B1 (en) | 1999-08-16 | 2004-05-18 | The United States Of America As Represented By The Department Of Health And Human Services | Receptor-mediated uptake of an extracellular BCL-xL fusion protein inhibits apoptosis |
| BR0013666A (pt) | 1999-08-27 | 2002-05-14 | Cytovia Inc | "alfa"-hidróxi-ácidos substituìdos inibidores de caspases e o seu uso |
| US6890896B1 (en) | 1999-11-18 | 2005-05-10 | Ceremedix, Inc. | Compositions and methods for counteracting effects of reactive oxygen species and free radicals |
| US6476048B1 (en) | 1999-12-07 | 2002-11-05 | Inotek Pharamaceuticals Corporation | Substituted phenanthridinones and methods of use thereof |
| US6531464B1 (en) | 1999-12-07 | 2003-03-11 | Inotek Pharmaceutical Corporation | Methods for the treatment of neurodegenerative disorders using substituted phenanthridinone derivatives |
| US6534651B2 (en) | 2000-04-06 | 2003-03-18 | Inotek Pharmaceuticals Corp. | 7-Substituted isoindolinone inhibitors of inflammation and reperfusion injury and methods of use thereof |
| GB0011095D0 (en) | 2000-05-08 | 2000-06-28 | Black James Foundation | astrin and cholecystokinin receptor ligands (III) |
| US6521617B2 (en) | 2000-10-13 | 2003-02-18 | The Johns Hopkins University | Treatment of apoptotic cell death |
| AU2002239595A1 (en) | 2000-12-15 | 2002-06-24 | Mitokor | Compounds for altering mitochondrial function and cellular responses |
| US7601846B2 (en) | 2001-06-26 | 2009-10-13 | The Regents Of The University Of California | Compounds having activity as inhibitors of apoptosis |
| CN1526011A (zh) | 2001-07-10 | 2004-09-01 | IDECҩ�﹫˾ | 抑制凋亡过程及改善细胞性能 |
| DE10144153A1 (de) | 2001-09-07 | 2003-03-27 | Newfrey Llc | Halteclip mit versetzten Rastfingern |
| BRPI0307673A2 (pt) | 2002-02-13 | 2016-11-08 | Beth Israel Hospital | métodos de tratar doença vascular. |
| BRPI0407757A (pt) | 2003-02-28 | 2006-02-14 | Inotek Pharmaceuticals Corp | derivados de benzamida tetracìclica e métodos de uso dos mesmos |
| US7449464B2 (en) | 2003-03-12 | 2008-11-11 | Kudos Pharmaceuticals Limited | Phthalazinone derivatives |
| US7268138B2 (en) | 2003-05-28 | 2007-09-11 | Mgi Gp, Inc. | Compounds, methods and pharmaceutical compositions for inhibiting PARP |
| JP4931604B2 (ja) | 2004-01-23 | 2012-05-16 | コーネル リサーチ ファウンデイション インコーポレイテッド | 酸化的損傷を低減する方法 |
| TWI375673B (en) | 2005-04-11 | 2012-11-01 | Abbott Lab | 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors |
| DE602006013191D1 (de) | 2005-11-15 | 2010-05-06 | Abbott Lab | Substituierte 1h-benzimidazol-4-carbonsäureamide sind wirksame parp-inhibitoren |
| US7528174B2 (en) | 2006-01-06 | 2009-05-05 | University Of Pittsburgh-Of The Commonwealth System Of Higher Education | Selective targeting agents for mitochondria |
| EP2079699A1 (en) * | 2006-07-25 | 2009-07-22 | Envivo Pharmaceuticals, Inc. | Quinoline derivatives |
| EP2139460A4 (en) * | 2007-03-20 | 2011-09-07 | Univ Brandeis | COMPOSITIONS AND METHODS FOR THE DIAGNOSIS, TREATMENT AND PREVENTION OF AMYOTROPHER LATERAL SCLEROSIS AND ASSOCIATED NEUROLOGICAL DISEASES |
| US8183236B2 (en) * | 2007-04-12 | 2012-05-22 | University Of Southern California | Compounds with HIV-1 integrase inhibitory activity and use thereof as anti-HIV/AIDS therapeutics |
| WO2008153760A1 (en) | 2007-05-25 | 2008-12-18 | Burnham Institute For Medical Research | Inhibitors of thapsigargin-induced cell death |
| US8138356B2 (en) * | 2007-10-16 | 2012-03-20 | Angiogeney, Inc. | Chemical inhibitors of inhibitors of differentiation |
| EP2300005A4 (en) * | 2008-05-28 | 2011-07-13 | Us Of America As Represented By The Secretary Of The Army On Behalf Of U S Army Medical Res And Mate | Small-molecule inhibitors of botulinum neurotoxins |
| US8658170B2 (en) * | 2010-01-06 | 2014-02-25 | Joseph P. Errico | Combination therapy with MDM2 and EFGR inhibitors |
| AU2011204368B2 (en) * | 2010-01-06 | 2014-11-27 | Joseph P. Errico | Methods and compositions of targeted drug development |
-
2010
- 2010-05-06 HU HU1000243A patent/HUP1000243A2/hu unknown
-
2011
- 2011-05-06 PT PT117523357T patent/PT2566849T/pt unknown
- 2011-05-06 EA EA201270787A patent/EA021026B1/ru unknown
- 2011-05-06 US US13/696,541 patent/US8871937B2/en active Active
- 2011-05-06 DK DK11752335.7T patent/DK2566849T3/da active
- 2011-05-06 JP JP2013508559A patent/JP5812541B2/ja active Active
- 2011-05-06 CN CN201180033524.5A patent/CN102985407B/zh active Active
- 2011-05-06 EP EP11752335.7A patent/EP2566849B1/en active Active
- 2011-05-06 NZ NZ603967A patent/NZ603967A/en unknown
- 2011-05-06 RS RS20191622A patent/RS59678B1/sr unknown
- 2011-05-06 MX MX2012012883A patent/MX337999B/es active IP Right Grant
- 2011-05-06 SI SI201131826T patent/SI2566849T1/sl unknown
- 2011-05-06 ES ES11752335T patent/ES2761832T3/es active Active
- 2011-05-06 PL PL11752335T patent/PL2566849T3/pl unknown
- 2011-05-06 CA CA2798419A patent/CA2798419C/en active Active
- 2011-05-06 KR KR1020127030702A patent/KR101837974B1/ko active IP Right Grant
- 2011-05-06 AU AU2011256989A patent/AU2011256989B2/en active Active
- 2011-05-06 WO PCT/HU2011/000043 patent/WO2011148208A1/en active Application Filing
- 2011-05-06 HU HUE11752335A patent/HUE050886T2/hu unknown
-
2019
- 2019-12-17 CY CY20191101327T patent/CY1122426T1/el unknown
- 2019-12-18 HR HRP20192278TT patent/HRP20192278T1/hr unknown
Also Published As
| Publication number | Publication date |
|---|---|
| NZ603967A (en) | 2014-06-27 |
| US8871937B2 (en) | 2014-10-28 |
| HUP1000243A2 (en) | 2012-01-30 |
| EP2566849A1 (en) | 2013-03-13 |
| SI2566849T1 (sl) | 2020-02-28 |
| HU1000243D0 (en) | 2010-06-28 |
| AU2011256989B2 (en) | 2014-08-21 |
| MX337999B (es) | 2016-03-30 |
| EA021026B1 (ru) | 2015-03-31 |
| EP2566849B1 (en) | 2019-09-18 |
| CN102985407B (zh) | 2015-09-09 |
| KR101837974B1 (ko) | 2018-03-13 |
| KR20130029772A (ko) | 2013-03-25 |
| MX2012012883A (es) | 2013-03-20 |
| CA2798419C (en) | 2021-01-05 |
| RS59678B1 (sr) | 2020-01-31 |
| HRP20192278T1 (hr) | 2020-03-06 |
| ES2761832T3 (es) | 2020-05-21 |
| PL2566849T3 (pl) | 2020-03-31 |
| HUE050886T2 (hu) | 2021-01-28 |
| US20130131096A1 (en) | 2013-05-23 |
| CN102985407A (zh) | 2013-03-20 |
| WO2011148208A1 (en) | 2011-12-01 |
| JP5812541B2 (ja) | 2015-11-17 |
| AU2011256989A1 (en) | 2013-01-10 |
| JP2013525473A (ja) | 2013-06-20 |
| PT2566849T (pt) | 2020-01-06 |
| CA2798419A1 (en) | 2011-12-01 |
| DK2566849T3 (da) | 2020-01-02 |
| EA201270787A1 (ru) | 2013-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1122426T1 (el) | Παραγωγα 8-υδροξυ-κινολινης | |
| CY1116945T1 (el) | Παραγωγα ινδολιζινης, διεργασια για την παρασκευη αυτης και θεραπευτικη χρηση αυτης | |
| CY1121724T1 (el) | Ενωσεις για την αντιμετωπιση καρκινου | |
| CY1121792T1 (el) | Ετεροκυκλικη ενωση | |
| CY1118390T1 (el) | Θεραπευτικος παραγων για τη φλεγμονωδη νοσο του εντερου | |
| CY1116405T1 (el) | Ν1/ν2-λακταμικοι αναστολεις ακετυλο-coa καρβοξυλασης | |
| HN2012001413A (es) | Derivados de pirazina y su uso en el tratamiento de trastornos neurólogicos | |
| CY1118102T1 (el) | Αλατα διαμινιου φαινοθειαζινης και η χρηση αυτων | |
| CO7141456A2 (es) | Derivados de aril-sultamo como moduladores de rorc | |
| NI201000107A (es) | Derivados de tiazol utilizados como inhibidores de pi 3 - cinasa. | |
| CY1117078T1 (el) | Παραγωγα 1-((5-ετεροαρυλθειαζολ-2-υλ) αμινοκαρβονυλ) πυρρολιδινο-2-καρβοξαμιδης ως αναστολεις φωσφατιδυλινοσιτολ 3-κινασης (ρι3κ) χρησιμα στη θεραπεια πολλαπλασιαστικων νοσων | |
| AR098912A1 (es) | Inhibidores de syk | |
| CY1116423T1 (el) | Ενωσεις δις(φθοροαλκυλο)-1,4-βενζοδιαζεπινονης | |
| CY1117193T1 (el) | Φαρμακευτικη συνθεση για θεραπεια ή αποτροπη γλαυκωματος | |
| CY1119842T1 (el) | Συντηγμενες τρικυκλικες ετεροκυκλικες ενωσεις ως αναστολεις ιντεγκρασης hiv | |
| CY1116333T1 (el) | Παραγωγα βενζοφουρανιου ως ρυθμιστικα μορια των fxr | |
| UY34451A (es) | Derivados de uracilo como inhibidores de la quinasa axl y c-met | |
| CY1123154T1 (el) | Παραγοντας ενισχυσης της επιδρασης αποκαταστασης μετα απο νευρικη βλαβη που περιλαμβανει ενα παραγωγο αλκυλαιθερα ή ενα αλας αυτου | |
| CY1120881T1 (el) | Ανταγωνιστες υποδοχεα 5-ητ3 | |
| UY32799A (es) | Derivados de oxazina y su uso en el tratamiento de trastornos neurológicos | |
| CY1123533T1 (el) | Ν-αλκυλαρυλο-5-οξυαρυλο-οκταϋδρο-κυκλοπεντα [c] πυρρολια ως αρνητικοι αλλοστερικοι ρυθμιστες των nr2b | |
| CY1118365T1 (el) | Διαμορφωτες διυδροπυραζολης του gpr40 | |
| CR20150378A (es) | Compuestos tetracíclicos sustituidos con heterociclo y métodos de uso de los mismos para el tratamiento de enfermedades víricas | |
| EA201490754A1 (ru) | Производные карбамата/мочевины, содержащие пиперидиновые и пиперазиновые кольца, в качестве ингибиторов н3 рецептора | |
| CY1119040T1 (el) | Μεθοδος για την παρασκευη 1-([1,3]διοξολαν-4-υλομεθυλο)-1η-πυραζολ-3-υλαμινης |